METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-LAG3 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY

1 - 43 . (canceled)

44 . A method of treating cancer, comprising administering to a human patient in need thereof:

(a) an anti-human PD-1 monoclonal antibody or antigen binding fragment thereof;

(b) an anti-human LAG3 monoclonal antibody or antigen binding fragment thereof; and

(c) an anti-human TIGIT monoclonal antibody or antigen binding fragment thereof;

wherein optionally the anti-human PD-1 monoclonal antibody is a human antibody or a humanized antibody;

wherein optionally the anti-human LAG3 monoclonal antibody is a human antibody or a humanized antibody; and

wherein optionally the anti-human TIGIT monoclonal antibody is a human antibody or a humanized antibody.

45 . The method of claim 44 , wherein the cancer is selected from the group consisting of osteosarcoma, rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal transitional cell cancer, bladder cancer, Wilm's cancer, ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, bone cancer, lung cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical cancer, synovial sarcoma, head and neck cancer, squamous cell carcinoma, lymphoma, diffuse large B-cell lymphoma, non-Hodgkin lymphoma, multiple myeloma, renal cell cancer, retinoblastoma, hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid tumor of the kidney, Ewing's sarcoma, chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary adenoma, vestibular schwannoma, primitive neuroectodermal tumor, medulloblastoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, polycythemia vera, thrombocythemia, idiopathic myelfibrosis, soft tissue sarcoma, thyroid cancer, endometrial cancer, and carcinoid cancer.

46 . A method of enhancing T cell activity, increasing cytokine production of T cells, or increasing proliferation of T cells, comprising contacting the T cells with:

(a) an anti-human PD-1 monoclonal antibody or antigen binding fragment thereof;

(b) an anti-human LAG3 monoclonal antibody or antigen binding fragment thereof; and

(c) an anti-human TIGIT monoclonal antibody or antigen binding fragment thereof;

wherein optionally the anti-human PD-1 monoclonal antibody is a human antibody or a humanized antibody;

wherein optionally the anti-human LAG3 monoclonal antibody is a human antibody or a humanized antibody; and

wherein optionally the anti-human TIGIT monoclonal antibody is a human antibody or a humanized antibody.

47 . A pharmaceutical composition or a kit, comprising:

(a) an anti-human PD-1 monoclonal antibody or antigen binding fragment thereof;

(b) an anti-human LAG3 monoclonal antibody or antigen binding fragment thereof; and

(c) an anti-human TIGIT monoclonal antibody or antigen binding fragment thereof;

wherein optionally the anti-human PD-1 monoclonal antibody is a human antibody or a humanized antibody;

wherein optionally the anti-human LAG3 monoclonal antibody is a human antibody or a humanized antibody; and

wherein optionally the anti-human TIGIT monoclonal antibody is a human antibody or a humanized antibody.

48 . The method of claim 44 , wherein the anti-human PD-1 monoclonal antibody or antigen binding fragment thereof

(i) comprises a light chain variable region (V L ) complementarity determining region 1 (CDR1), a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:1, 2, and 3, respectively, and a heavy chain variable region (V H ) CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:6, 7, and 8, respectively;

(ii) comprises a V L region comprising an amino acid sequence as set forth in SEQ ID NO:4, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:9;

(iii) comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:10;

(iv) comprises a light chain variable region (V L ) complementarity determining region 1 (CDR1), a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:31, 32, and 33, respectively, and a heavy chain variable region (V H ) CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:36, 37, and 38, respectively;

(v) comprises a V L region comprising an amino acid sequence as set forth in SEQ ID NO:34, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:39;

(vi) comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:35 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:40;

(vii) is pembrolizumab;

(viii) is nivolumab; or

(ix) is cemiplimab.

49 . The method of claim 44 , wherein the anti-human LAG3 monoclonal antibody or antigen binding fragment thereof comprises

(i) a V L CDR1, a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:11, 12, and 13, respectively, and a V H CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:16, 17, and 18, respectively;

(ii) a V L region comprising an amino acid sequence as set forth in SEQ ID NO:14, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:19; or

(iii) a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:15 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:20.

50 . The method of claim 44 , wherein the anti-human TIGIT monoclonal antibody or antigen binding fragment thereof comprises

(i) a V L CDR1, a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:21, 22, and 23, respectively, and a V H CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:26, 27, and 28, respectively;

(ii) a V L region comprising an amino acid sequence as set forth in SEQ ID NO:24, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:29; or

(iii) a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:25 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:30.

51 . The method of claim 44 , wherein:

(i) (a) the anti-human PD-1 monoclonal antibody or antigen binding fragment thereof comprises a V L CDR1, a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:1, 2, and 3, respectively, and a V H CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:6, 7, and 8, respectively;

(b) the anti-human LAG3 monoclonal antibody or antigen binding fragment thereof comprises a V L CDR1, a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:11, 12, and 13, respectively, and a V H CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:16, 17, and 18, respectively; and

(c) the anti-human TIGIT monoclonal antibody or antigen binding fragment thereof comprises a V L CDR1, a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:21, 22, and 23, respectively, and a V H CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:26, 27, and 28, respectively;

(ii) (a) the anti-human PD-1 monoclonal antibody or antigen binding fragment thereof comprises a V L region comprising an amino acid sequence as set forth in SEQ ID NO:4, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:9;

(b) the anti-human LAG3 monoclonal antibody or antigen binding fragment thereof comprises a V L region comprising an amino acid sequence as set forth in SEQ ID NO:14, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:19; and

(c) the anti-human TIGIT monoclonal antibody or antigen binding fragment thereof comprises a V L region comprising an amino acid sequence as set forth in SEQ ID NO:24, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:29;

(iii) (a) the anti-human PD-1 monoclonal antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:10;

(b) the anti-human LAG3 monoclonal antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:15 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:20; and

(c) the anti-human TIGIT monoclonal antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:25 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:30;

(iv) (a) the anti-human PD-1 monoclonal antibody or antigen binding fragment thereof comprises a V L CDR1, a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:31, 32, and 33, respectively, and a V H CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:36, 37, and 38, respectively;

(b) the anti-human LAG3 monoclonal antibody or antigen binding fragment thereof comprises a V L CDR1, a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:11, 12, and 13, respectively, and a V H CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:16, 17, and 18, respectively; and

(c) the anti-human TIGIT monoclonal antibody or antigen binding fragment thereof comprises a V L CDR1, a V L CDR2, and a V L CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:21, 22, and 23, respectively, and a V H CDR1, a V H CDR2, and a V H CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:26, 27, and 28, respectively;

(v) (a) the anti-human PD-1 monoclonal antibody or antigen binding fragment thereof comprises a V L region comprising an amino acid sequence as set forth in SEQ ID NO:34, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:39;

(b) the anti-human LAG3 monoclonal antibody or antigen binding fragment thereof comprises a V L region comprising an amino acid sequence as set forth in SEQ ID NO:14, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:19; and

(c) the anti-human TIGIT monoclonal antibody or antigen binding fragment thereof comprises a V L region comprising an amino acid sequence as set forth in SEQ ID NO:24, and a V H region comprising an amino acid sequence as set forth in SEQ ID NO:29; or

(vi) (a) the anti-human PD-1 monoclonal antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:35 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:40;

(b) the anti-human LAG3 monoclonal antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:15 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:20; and

(c) the anti-human TIGIT monoclonal antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:25 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:30.

52 . The method of claim 48 (vii), wherein the human patient is administered 200 mg, 240 mg, or 2 mg/kg pembrolizumab, and wherein pembrolizumab is administered once every three weeks.

53 . The method of claim 48 (vii), wherein the human patient is administered 400 mg pembrolizumab, and wherein pembrolizumab is administered once every six weeks.

54 . The method of claim 48 (viii), wherein the human patient is administered 240 mg or 3 mg/kg nivolumab, and wherein nivolumab is administered once every two weeks.

55 . The method of claim 48 (ix), wherein the human patient is administered 350 mg cemiplimab, and wherein cemiplimab is administered once every three weeks.